Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal.
暂无分享,去创建一个
G. Mowatt | C. Fraser | X. Jia | M. Crowther | C. Boachie | R. Hernández | X. Jia | L. Ternent | M. Crowther | R. Hernández
[1] J. Bernard,et al. Treatment of adult autoimmune thrombocytopenic purpura with high-dose intravenous plasmin-cleaved gammaglobulins. , 2009, Scandinavian journal of haematology.
[2] F. Goebel,et al. Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus. , 2009, Scandinavian journal of haematology.
[3] R. Fanin,et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long‐term follow‐up results , 2008, European journal of haematology.
[4] R. Porcher,et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. , 2008, Blood.
[5] E. Vellenga,et al. EVALUATING THE LONG-TERM EFFICACY OF ROMIPLOSTIM (AMG 531) IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) DURING AN OPEN-LABEL EXTENSION STUDY , 2008 .
[6] R. Fanin,et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura , 2008, Haematologica.
[7] J. George,et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.
[8] S. Amadori,et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults , 2007, Haematologica.
[10] J. Bussel,et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. , 2007, The New England journal of medicine.
[11] T. Nagasawa,et al. A Phase 2 Open-Label, Sequential-Cohort, Dose-Escalation Study of AMG 531 in Japanese Patients with Chronic Immune Thrombocytopenic Purpura (ITP). , 2007 .
[12] T. Guthrie,et al. Reduction in immunoglobulin (IVIG or anti D) use in patients with chronic immune thrombocytopenic purpura (ITP) receiving AMG 531 , 2007 .
[13] J. Logie,et al. Risk of Cataracts among Idiopathic Thrombocytopenic Purpura (ITP) Patients in the UK General Practice Research Database (GPRD). , 2007 .
[14] R. Fanin,et al. A prospective randomized study of rituximab and dexamethasone vs dexamethasone alone in ITP , 2007 .
[15] T. Robak,et al. Efficacy and Safety of a New Intravenous Immunoglobulin Product in Patients with Chronic Immune Thrombocytopenic Purpura. , 2007 .
[16] A. Flahault,et al. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. , 2007, Journal of the American Academy of Dermatology.
[17] A. Majluf-Cruz,et al. Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis , 2007, Annals of Hematology.
[18] J. Bussel,et al. Immune thrombocytopenic purpura in adults , 2007, Current opinion in hematology.
[19] T. Robak,et al. Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac®) in chronic immune thrombocytopenic purpura , 2007, Hematology.
[20] A. Ho,et al. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab , 2007, Annals of Hematology.
[21] Jian Wang,et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. , 2007, Journal of the National Cancer Institute.
[22] A. Matzdorff,et al. Treatment of chronic immune thrombocytopenic purpura: the patients’ perspective , 2007, European journal of haematology.
[23] J. Bussel,et al. Safety and tolerability of a novel chromatography‐based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura , 2007, American journal of hematology.
[24] M. Erkurt,et al. Retrospective Analysis of Patients with Idiopathic Thrombocytopenic Purpura from Eastern Anatolia , 2007, Medical Principles and Practice.
[25] F. Dentali,et al. Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura , 2007, Annals of Internal Medicine.
[26] J. Bussel,et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura : 2-year update , 2006 .
[27] J. Sierra,et al. Study on the Efficacy and Safety of IGIV3I Grifols (Human Intravenous Immunoglobulin) in Patients Diagnosed with Chronic Immune Thrombocytopenic Purpura. , 2006 .
[28] J. Christal,et al. An open‐label, unit dose‐finding study of AMG 531, a novel thrombopoiesis‐stimulating peptibody, in patients with immune thrombocytopenic purpura , 2006, British journal of haematology.
[29] J. George,et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. , 2006, The New England journal of medicine.
[30] J. George. Management of patients with refractory immune thrombocytopenic purpura , 2006, Journal of thrombosis and haemostasis : JTH.
[31] P. Cernelc,et al. Cyclosporin A as an Immunosuppressive Treatment Modality for Patients with Refractory Autoimmune Thrombocytopenic Purpura after Splenectomy Failure , 2006, International journal of hematology.
[32] M. Loh,et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. , 2006, Blood.
[33] F. Peñalver,et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients , 2006, Annals of Hematology.
[34] S. Golder,et al. Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. , 2006, Health information and libraries journal.
[35] R. Fanin,et al. Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. , 2005, Experimental hematology.
[36] J. George,et al. Long-Term Dosing of AMG 531 Is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura. , 2005 .
[37] D. Case,et al. Rituximab Produces Long-Term Responses in Immune Thrombocytopenic Purpura (ITP). , 2005 .
[38] J. Vela-Ojeda,et al. Treatment of Refractory Chronic Immune Thrombocytopaenic Purpura (ITP) with Rituximab: Report of a Cases Series. , 2005 .
[39] B. George,et al. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults – a report on 90 patients , 2005, European journal of haematology.
[40] K. Ramadan,et al. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. , 2005, Clinical and laboratory haematology.
[41] O. Lambotte,et al. Efficacy of mycophenolate mofetil in adult refractory auto‐immune cytopenias: a single center preliminary study , 2005, European journal of haematology.
[42] T. Plesner,et al. Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura , 2005, American journal of hematology.
[43] J. Bussel,et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. , 2005, The Journal of pediatrics.
[44] Lei Zhang,et al. Chronic idiopathic thrombocytopenic purpura in adult Chinese patients: a retrospective single-centered analysis of 1791 cases. , 2005, Chinese medical journal.
[45] T. Guthrie,et al. Rituximab Induces High Response Rate and Prolonged Remission in Chronic Idiopathic Thrombocytopenic Purpura (ITP): A Retrospective Analysis. , 2004 .
[46] I. Tabbara,et al. The Use of Anti-CD20 Chimeric Monoclonal Antibody, Rituximab in Adult Patients with Treatment Refractory Immune Thrombocytopenia. , 2004 .
[47] Chien-Feng Chen,et al. An Open-Label, Unit Dose-Finding Study Evaluating the Safety and Platelet Response of a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (Pts) with Immune Thrombocytopenic Purpura (ITP). , 2004 .
[48] A. Jajeh,et al. Rituximab in the Treatment of Adults with Chronic Idiopathic Thrombocytopenic Purpura (ITP) and Autoimmune Hemolytic Anemia (AIHA). , 2004 .
[49] S. Vesely,et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. , 2004, Blood.
[50] R. Mcmillan,et al. Long-term outcomes in adults with chronic ITP after splenectomy failure. , 2004, Blood.
[51] E. Andrès,et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. , 2004, The American journal of medicine.
[52] E. Andrès,et al. Current management of adult idiopathic thrombocytopenic purpura in practice: a cohort study of 201 patients from a single center. , 2004, Clinical and laboratory haematology.
[53] J. Leonard,et al. The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura , 2004, British journal of haematology.
[54] A. Canataroğlu,et al. Anti-D and Intravenous Immunoglobulin Treatments in Chronic Idiopathic Thrombocytopenic Purpura. , 2004, Turkish journal of haematology : official journal of Turkish Society of Haematology.
[55] A. Angiolillo,et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life , 2004, Thrombosis and Haemostasis.
[56] S. Vesely,et al. Management of Adult Patients with Persistent Idiopathic Thrombocytopenic Purpura Following Splenectomy , 2004, Annals of Internal Medicine.
[57] J. Penner,et al. Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab) , 2003, American journal of hematology.
[58] T. Shanafelt,et al. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. , 2003, Mayo Clinic proceedings.
[59] S. Vesely,et al. Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti‐D with routine care , 2003, American journal of hematology.
[60] Shaji K. Kumar,et al. Treatment advances in adult immune thrombocytopenic purpura , 2003, Annals of Hematology.
[61] F. Song,et al. Evaluating non-randomised intervention studies. , 2003, Health technology assessment.
[62] S. Proctor,et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population‐based cohort of 245 patients , 2003, British journal of haematology.
[63] M. Hou,et al. Mycophenolate mofetil (MMF) for the treatment of steroid‐resistant idiopathic thrombocytopenic purpura , 2003, European journal of haematology.
[64] N. Xing,et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. , 2003, Blood.
[65] W. Ouwehand,et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy , 2003, British journal of haematology.
[66] P. Williams,et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies , 2003, Vox sanguinis.
[67] U. Germing,et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti‐CD20 monoclonal antibody rituximab: a pilot study , 2002, European journal of haematology.
[68] A. Tefferi,et al. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses , 2002, Annals of Hematology.
[69] A. Hoffbrand,et al. Mycophenolate mofetil for the treatment of refractory auto‐immune haemolytic anaemia and auto‐immune thrombocytopenia purpura , 2002, British journal of haematology.
[70] S. Amadori,et al. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. , 2002, Blood.
[71] J. Bussel,et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? , 2002, Blood.
[72] R. Marasca,et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. , 2002, Blood.
[73] S. Chevret,et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial , 2002, The Lancet.
[74] S. Amadori,et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. , 2001, Blood.
[75] M. V. van't Veer,et al. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy , 2001, British journal of haematology.
[76] T. Dutta,et al. Dapsone in treatment of chronic idiopathic thrombocytopenic purpura in adults. , 2001, The Journal of the Association of Physicians of India.
[77] J. Bussel,et al. A dose of 75 μg/kg/d of i.v. anti‐D increases the platelet count more rapidly and for a longer period of time than 50 μg/kg/d in adults with immune thrombocytopenic purpura , 2001 .
[78] G. Dolan,et al. Vigam‐S, a solvent/detergent‐treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura , 2001, Transfusion medicine.
[79] J. Gutheil,et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. , 2000, Seminars in oncology.
[80] S. Amadori,et al. Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. , 2000, Blood cells, molecules & diseases.
[81] B. Djulbegovic,et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. , 2000, Archives of internal medicine.
[82] P. Bierling,et al. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. , 1999, British journal of haematology.
[83] K. Schmidt,et al. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. , 1999, Blood.
[84] M. Goldaniga,et al. ADULT REFRACTORY CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA: CAN DAPSONE BE PROPOSED AS SECOND‐LINE THERAPY? , 1999, British journal of haematology.
[85] A D Oxman,et al. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials , 1998, BMJ.
[86] D. Albayrak,et al. Oral high‐dose methylprednisolone and intravenous immunoglobulin treatments in adult chronic idiopathic thrombocytopenic purpura , 1997, American journal of hematology.
[87] I. Reid. Glucocorticoid osteoporosis--mechanisms and management. , 1997, European journal of endocrinology.
[88] É. Oksenhendler,et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases , 1997, British journal of haematology.
[89] J. Bussel,et al. Intravenous Anti-D Treatment of Immune Thrombocytopenic Purpura: Experience in 272 Patients , 1997 .
[90] R. Mcmillan. Therapy for Adults with Refractory Chronic Immune Thrombocytopenic Purpura , 1997, Annals of Internal Medicine.
[91] J. George,et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. , 1996, Blood.
[92] G. Longo,et al. Long‐term salvage treatment by cyclosporin in refractory autoimmune haematological disorders , 1996, British journal of haematology.
[93] R. Espínola,et al. [Treatment of idiopathic thrombocytopenic purpura with danazol]. , 1995, Sangre.
[94] A. Perez,et al. Dapsone for refractory chronic idiopathic thrombocytopenic purpura , 1995, British journal of haematology.
[95] G. Papa,et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. , 1995, The American journal of medicine.
[96] F. Rodeghiero,et al. Failure of repeated courses of high-dose intravenous immunoglobulin to induce stable remission in patients with chronic idiopathic thrombocytopenic purpura , 1995, Annals of Hematology.
[97] A. Reiner,et al. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. , 1995, Blood.
[98] P. Bierling,et al. Dapsone for idiopathic thrombocytopenic purpura , 1994, American journal of hematology.
[99] P. Jacobs,et al. Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia: a prospective randomized clinical trial. , 1994, The American journal of medicine.
[100] E. Wattel,et al. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients , 1994, British journal of haematology.
[101] D. Donovan. Prospective or retrospective? , 1993, Journal of public health medicine.
[102] F. Rodeghiero,et al. Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. , 1993, Haematologica.
[103] P. Bierling,et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. , 1993, Blood.
[104] É. Oksenhendler,et al. Dapsone for autoimmune thrombocytopenic purpura , 1993, American journal of hematology.
[105] M. Ohto,et al. Danazol therapy in idiopathic thrombocytopenic purpura: the efficacy of low-medium dose therapy. , 1992, International journal of hematology.
[106] F. Rodeghiero,et al. A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins. , 1992, Haematologica.
[107] A. Manoharan. Targeted‐immunosuppression with vincristine infusion in the treatment of immune thrombocytopenia , 1991, Australian and New Zealand journal of medicine.
[108] D. Meytes,et al. Danazol in non-splenectomized patients with refractory idiopathic thrombocytopenic purpura. , 1990, Postgraduate medical journal.
[109] P. Fenaux,et al. Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: A report on 43 cases , 1990, Blut.
[110] J. Bussel,et al. Alternation of two doses of intravenous gammaglobulin in the maintenance treatment of patients with immune thrombocytopenic purpura: More is not always better , 1990, American journal of hematology.
[111] L. Raisz,et al. Glucocorticoid-induced osteoporosis: pathogenesis and management. , 1990, Annals of internal medicine.
[112] P. Fenaux,et al. Re‐evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases , 1990, British journal of haematology.
[113] R. Mylvaganam,et al. Very low dose danazol in idiopathic thrombocytopenic purpura and its role as an immune modulator. , 1989, The American journal of the medical sciences.
[114] T. Baglin,et al. The treatment of chronic idiopathic thrombocytopenia with anti-D (Rho) immunoglobulin: its effectiveness, safety and mechanism of action. , 1988, Clinical and laboratory haematology.
[115] J. Bussel,et al. Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. , 1988, Blood.
[116] A. Manoharan. Danazol therapy in patients with immune cytopenias. , 1987, Australian and New Zealand journal of medicine.
[117] A. Avilés,et al. Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP). , 1987, Nouvelle revue francaise d'hematologie.
[118] R. Coleman,et al. Comparison of the efficacy of a two-day and a five-day schedule for infusing intravenous gamma globulin in the treatment of immune thrombocytopenic purpura in adults. , 1987, The American journal of medicine.
[119] P. Fenaux,et al. The treatment of adult idiopathic thrombocytopenic purpura , 1987, European journal of haematology.
[120] R. Mylvaganam,et al. Low-dose danazol therapy in idiopathic thrombocytopenic purpura. , 1987, Annals of internal medicine.
[121] P. Chien,et al. Effect of danazol in immune thrombocytopenic purpura. , 1987, The New England journal of medicine.
[122] A. Salama,et al. Effect of IgG anti‐Rho(D) in adult patients with chronic autoimmune thrombocytopenia , 1986, American journal of hematology.
[123] R. Clarke. Nausea and vomiting. , 1986, British journal of anaesthesia.
[124] A. Manoharan. Slow infusion of vincristine in the treatment of idiopathic thrombocytopenic purpura , 1986, American journal of hematology.
[125] B. Mcverry,et al. The use of danazol in the management of chronic immune thrombocytopenic purpura , 1985, British journal of haematology.
[126] M. Morales-Polanco,et al. Danazol in refractory autoimmune thrombocytopenic purpura (ATP). A new therapeutic sequence. , 1985, Archivos de investigacion medica.
[127] C. Bharucha,et al. Fresh frozen plasma in the treatment of chronic autoimmune thrombocytopenic purpura in adults: evidence for potentiating effect of vincristine. , 1985, Clinical and laboratory haematology.
[128] J. Pizzuto,et al. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. , 1984, Blood.
[129] J. Bergerat,et al. High-dose intravenous IgG for chronic idiopathic thrombocytopenic purpura in adults , 1984, Blut.
[130] A. Salama,et al. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)) , 1984, Blut.
[131] J. Akatsuka,et al. A Cooperative Clinical Trial of High-Dose Immunoglobulin Therapy in 177 Cases of Idiopathic Thrombocytopenic Purpura , 1984, Thrombosis and Haemostasis.
[132] J. Lewis,et al. Intravenous gamma globulin in the treatment of chronic idiopathic thrombocytopenic purpura in adults. , 1984, The American journal of medicine.
[133] W. Rosse,et al. Intravenous immunoglobulin administration in the treatment of severe chronic immune thrombocytopenic purpura. , 1984, The American journal of medicine.
[134] J. Lavery. Rho(D) immune globulin. When to use it in the Rho(D)-negative woman. , 1984, Postgraduate medicine.
[135] R. Mylvaganam,et al. Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. , 1984, Annals of internal medicine.
[136] J. Matsuda,et al. Clinical effect of intravenous immunoglobulin on chronic idiopathic thrombocytopenic purpura , 1983, Blut.
[137] A. Salama,et al. EFFECT OF INTRAVENOUS IMMUNOGLOBULIN IN IMMUNE THROMBOCYTOPENIA Competitive Inhibition of Reticuloendothelial System Function by Sequestration of Autologous Red Blood Cells? , 1983, The Lancet.
[138] R. Mylvaganam,et al. Danazol for the treatment of idiopathic thrombocytopenic purpura. , 1983, The New England journal of medicine.
[139] A. Newland,et al. HIGH-DOSE INTRAVENOUS IgG IN ADULTS WITH AUTOIMMUNE THROMBOCYTOPENIA , 1983, The Lancet.
[140] Kueh Yk. Vincristine therapy in refractory chronic idiopathic thrombocytopenic purpura. , 1982 .
[141] T. Wong,et al. The reversible binding of vinblastine to platelets: implications for therapy. , 1981, Blood.
[142] V. Picozzi,et al. Fate of therapy failures in adult idiopathic thrombocytopenic purpura. , 1980, The American journal of medicine.
[143] E. Montserrat,et al. Low-dose vincristine in the treatment of corticosteroid-refractory idiopathic thrombocytopenic purpura (ITP) in non-splenectomized patients. , 1980, Postgraduate medical journal.
[144] S. Boonpucknavig,et al. Chronic immunologic thrombocytopenic purpura: results of cyclophosphamide therapy before splenectomy. , 1980, Archives of internal medicine.
[145] D. Mohanty,et al. Idiopathic thrombocytopenic purpura (I.T.P.); clinico-pathological study of 30 cases. , 1979, The Journal of the Association of Physicians of India.
[146] Deborah S. Smith,et al. The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets. , 1978, The New England journal of medicine.
[147] J. Child,et al. Responses to cinvristine in refractory idiopathic thrombocytopenic purpura. , 1976, British medical journal.
[148] Y. Ahn,et al. Vincristine therapy of idiopathic and secondary thrombocytopenias. , 1974, The New England journal of medicine.
[149] E. Damasio,et al. Vinblastine sulphate in idiopathic thrombocytopenic purpura. , 1971, Lancet.
[150] R. Laros,et al. "Refractory" thrombocytopenic purpura treated successfully with cyclophosphamide. , 1971, JAMA.
[151] T. Makino,et al. [Refractory idiopathic thrombocytopenic purpura]. , 1969, Naika. Internal medicine.
[152] B. Bouroncle,et al. Treatment of refractory idiopathic thrombocytopenic purpura. , 1968, JAMA.
[153] L. Sussman. Azathioprine in refractory idiopathic thrombocytopenic purpura. , 1967, JAMA.
[154] C. Corley,et al. Azathioprine therapy of "autoimmune" diseases. , 1966, The American journal of medicine.
[155] M. Baldini. Idiopathic thrombocytopenic purpura. , 1966, The New England journal of medicine.
[156] V. Preedy,et al. Effect of 4-Week Heartfulness Meditation on Stress Scores, Sleep Quality, and Oxidative and Inflammatory Biochemical Parameters in COVID-19 Patients after Completion of Standard Treatment – A Randomized Controlled Trial , 2022, International journal of yoga.
[157] Zeping Zhou,et al. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. , 2008, Critical reviews in oncology/hematology.
[158] T. Taube,et al. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. , 2005, Haematologica.
[159] D. Cines,et al. Management of adult idiopathic thrombocytopenic purpura. , 2005, Annual review of medicine.
[160] A. Mehta,et al. Rituximab in the treatment of refractory autoimmune cytopenias in adults. , 2005, Haematologica.
[161] C. Mueller-Eckhardt,et al. High dose gammaglobulin therapy in adults with idiopathic thrombocytopenic purpura (ITP) clinical effects , 2004, Blut.
[162] A. Bogdanović,et al. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. , 2003, The hematology journal : the official journal of the European Haematology Association.
[163] R. Fanin,et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. , 2003, Haematologica.
[164] G. Gutiérrez-Espíndola,et al. High doses of dexamethasone in adult patients with idiopathic thrombocytopenic purpura. , 2003, Archives of medical research.
[165] R. Fanin,et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. , 2002, Haematologica.
[166] S. Tura,et al. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. , 2001, Haematologica.
[167] Shaji K. Kumar,et al. Splenectomy for adult immune thrombocytopenio purpura and treatment of post-splenectomy relapses , 2000 .
[168] U. Coşkun,et al. Long Term Follow-Up of 26 Patients With Adult Idiopathic Thrombocytopenic Purpura , 1999 .
[169] O. Samoilova,et al. [Treatment of idiopathic thrombocytopenic purpura in adults: efficacy of domestic intravenous immunoglobulin in immune thrombocytopenia]. , 1999, Terapevticheskii arkhiv.
[170] Aksenov Av,et al. Movalis treatment of low back pain (LBP) , 1999 .
[171] A. Eldor,et al. Clinical and Therapeutic Experience in 712 Israeli Patients with Idiopathic Thrombocytopenic Purpura , 1994 .
[172] T. Barbui,et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. , 1991, Blood.
[173] P. Fenaux,et al. The role of danazol in the treatment of refractory idiopathic thrombocytopenic purpura. A report of 22 cases. , 1990, Nouvelle revue francaise d'hematologie.
[174] S. Asano,et al. Clinical usefulness of vinca alkaloid slow infusion in the treatment of chronic refractory idiopathic thrombocytopenic purpura: a multicenter cooperative study. , 1990, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society.
[175] W. Tyminski,et al. [Use of vincristine-loaded blood platelets, danazol and gamma globulin in the treatment of patients with idiopathic thrombocytopenic purpura]. , 1989, Acta haematologica Polonica.
[176] M. Linares,et al. Slow infusion of vincristine in the treatment of refractory thrombocytopenic purpura. , 1988, Acta haematologica.
[177] E. Ascari,et al. Danazol therapy for idiopathic thrombocytopenic purpura (ITP). , 1988, Haematologica.
[178] M. Podolak-Dawidziak,et al. Danazol in chronic idiopathic thrombocytopenic purpura resistant to corticosteroids. , 1987, Folia haematologica.
[179] M. Mazzucconi,et al. Danazol therapy in refractory chronic immune thrombocytopenic purpura. , 1987, Acta haematologica.
[180] D. Almagro. Danazol in idiopathic thrombocytopenic purpura. , 1985, Acta haematologica.
[181] T. Barbui,et al. Danazol for the treatment of idiopathic thrombocytopenic purpura. , 1985, Acta haematologica.
[182] S. Tarui,et al. High-dose gammaglobulin therapy for idiopathic thrombocytopenic purpura in adults. , 1983, Acta haematologica.
[183] R. Laros,et al. Treatment of refractory thrombocytopenic purpura with cyclophosphamide , 1976, American journal of hematology.